(not currently available) and may persist for 3 to 6 months. The actual incidence of hypertension in women taking OCs is not known; however, women using lower doses of estrogen (less than 35 μg) have a very low incidence of elevated blood pressure (4/1,000) [37]. Other modifiable ...
To analyze this effect, we tested possible alternatives for the interaction between E 2 , colony-stimulating factor (CSF) and GM colony progenitor cells. E 2 was found not to interact synergistically with CSF, but pre-treatment of the progenitor cells with E 2 resulted in higher numbers of ...
Although numerous clinical studies have demonstrated the beneficial effect of preventing postmenopausal bone loss in elder women by long-term estrogen administration, effects of estrogen at the cellular level still remain unclear. Efforts to determine the precise role of bone cells in estrogen-mediated ...
Estradiol transdermal system (twice-weekly) is contraindicated in women with any of the following conditions: • Undiagnosed abnormal genital bleeding [see Warnings and Precautions (5.2)]. • Breast cancer or a history of breast cancer [see Warnings and Precautions (5.2)]. • Estrogen-dependen...
Large numbers of hormone replacement therapies (HRTs) are available for the treatment of menopausal symptoms. It is still unclear whether some are more del... A Fournier,BF Clavel-Chapelon - 《Breast Cancer Research & Treatment》 被引量: 495发表: 2008年 Hormonal regulation of apoptosis in bre...
Generally, a woman without a uterus does not need to use a progestogen in addition to her estrogen therapy. In some cases, however, hysterectomized women with a history ofendometriosismay need a progestogen [seeWARNINGS AND PRECAUTIONS]. ...
The influence of estradiol-17β (E2) overdose on the number and distribution of neurons in the dorsal root ganglia (DRGs) supplying the ovary of adult pigs was investigated. The numbers of ovarian substance P (SP)-, calcitonin gene-related peptide (CGRP)-, galanin (GAL)-, pituitary adenylat...
Breast cancer brain metastases (BM) affect younger women disproportionally, including those lacking estrogen receptor (ER), progesterone receptor, and HER2 (known as triple-negative breast cancer; TNBC). Previous studies in preclinical models showed that
This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, COCs, including desogestrel and ethinyl estradiol tablets and ethinyl estradiol tablets, are contraindicated in women who are over 35 years of age and smoke (...
consider addition of a progestogen to reduce the risk of endometrial cancer. Generally, a woman without a uterus does not need to use a progestogen in addition to her estrogen therapy. In some cases, however, hysterectomized women with a history ofendometriosismay need a progestogen [seeWARNING...